Charleston, SC -- (SBWIRE) -- 09/20/2013 -- Today’s Penny Stocks wants you, the investor, to have the ability to be informed in your trading decisions. Our website is designed to take you to the information you need to be at the top of your game in trading penny stocks. Today’s Penny Stocks issues news updates on the following stock: Gafisa SA (ADR) (NYSE:GFA), Triangle Petroleum Corporation (NYSEMKT:TPLM), Geron Corporation (NASDAQ:GERN), Exelixis, Inc. (NASDAQ:EXEL).
Gafisa SA (ADR) (NYSE:GFA) opened its last trade at the price of $3.40. Its closing price was $3.32 after losing -2.35% for the day. The company traded with the total volume of 2,233,010 shares, while its average trading volume remained 1.90 million shares. The beta of this stock stands at 2.57. Gafisa S.A. operates as a homebuilder in Brazil. The company operates in three segments: Gafisa, Tenda, and Alphaville. It engages in the development of residential buildings, including luxury buildings with swimming pools, gyms, visitor parking, and other amenities for upper-income customers.
Has GFA Found The Bottom and Ready To Move Up? Find Out Here
Triangle Petroleum Corporation (NYSEMKT:TPLM) percentage change surged 3.26% to close at $9.82 with the total traded volume of 2,213,110 shares, along with average volume of 1.62 million. The 52 week range of the stock remained $4.85 - $10.01, while its day lowest price was $9.39. The share price hit the day highest price of $10.01. Triangle Petroleum Corporation engages in the acquisition, exploration, development, and production of unconventional shale oil and natural gas resources in the Bakken Shale and Three Forks formations in the Williston Basin of North Dakota and Montana.
For How Long TPLM’s Gloss will Attract Investors? Find Out Here
Geron Corporation (NASDAQ:GERN) traded on volume of 2,172,510 shares in the last session against average volume of 1.07 million shares. The company started its trading session with the price of $2.74 and closed at $2.65 by scoring -1.12%. Geron Corporation is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.
Why Should Investors Buy GERN After the Recent Fall? Find Out Here
Exelixis, Inc. (NASDAQ:EXEL) started its last trading session with the price of $5.51 and closed at $5.61 by scoring +1.81%. The stock traded with total volume of 2,159,344 shares, while the average trading volume remained 1.46 million shares. The beta value of this stock stands at 1.94. Day range for the stock was $5.45- $5.62. Exelixis, Inc., a biotechnology company, engages in developing small molecule therapies for the treatment of cancer in the United States. It focuses on developing and commercializing COMETRIQ (cabozantinib), an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive, metastatic medullary thyroid cancer.
Why Should Investors Buy EXEL After The Recent Gain? Find Out Here
About Today’s Penny Stocks:
Today’s Penny Stocks wants you, the investor, to have the ability to be informed in your trading decisions. Our website is designed to take you to the information you need to be at the top of your game in trading penny stocks. Today’s wants you to do your own due diligence on your investments please use our site to find the information you need on whichever investment you choose.
The disclaimer is to be read and fully understood before using our site, or joining our newsletter email list. Never invest into a stock discussed on this web site or the TodaysPennyStocks.com newsletter unless you can afford to lose your entire investment.
Please consult with a certified financial advisor before making any investment decisions.
TodaysPennyStocks.com is owned and operated by FlipVentures LLC. We are engaged in the business of advertising and promoting companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities.
Read Full Disclaimer at: http://todayspennystocks.com/disclaimer/
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)